Literature DB >> 16196298

Tumor necrosis factor-related apoptosis ligand induces apoptosis in prostate cancer PC-3M cell line.

Zhaohui Chen1, Huafang Wang, Longjie Gu, Zhewei Ye, Yajun Xiao.   

Abstract

To study the effect of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) on PC-3M cell line, PC-3M cell line was incubated with gradient concentrations of TRAIL for 4--24 h. Annixin-V fluorescence staining and TUNEL method were employed to detect the apoptosis of PC-3M cells. The morphology of apoptotic PC-3M cells was observed by electron microscopy. The relationship between TRAIL concentrations and the percentage of apoptotic cells was evaluated by flow cytometry. The proliferation inhibitory ratio was calculated by using MTT colorimetry. Our results showed that apoptosis of PC-3M cells could be induced by treatment with TRAIL for at most 4 h. The results of flow cytometry and MTT colorimetry demonstrated a time- and concentration-dependent relationship between cell apoptosis rate and TRAIL concentration. It is concluded that apoptosis of PC-3M cells can be induced by TRAIL. Because of the selective killing effect of TRAIL on tumor cells, it may become a potential alternative for the treatment of advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196298     DOI: 10.1007/bf02828218

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs.

Authors:  S Vignati; A Codegoni; F Polato; M Broggini
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

2.  TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.

Authors:  M Plasilova; J Zivny; J Jelinek; R Neuwirtova; J Cermak; E Necas; L Andera; T Stopka
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

3.  The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  N Ozoren; K Kim; T F Burns; D T Dicker; A D Moscioni; W S El-Deiry
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

4.  Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines.

Authors:  G Jenster
Journal:  J Pathol       Date:  2000-07       Impact factor: 7.996

5.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

8.  Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.

Authors:  S Shetty; J Brown Gladden; E S Henson; X Hu; J Villanueva; N Haney; S B Gibson
Journal:  Apoptosis       Date:  2002-10       Impact factor: 4.677

9.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

Authors:  M M Keane; S A Ettenberg; M M Nau; E K Russell; S Lipkowitz
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.

Authors:  Vijayanand Modur; Rakesh Nagarajan; B Mark Evers; Jeffrey Milbrandt
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.